Yalta, KenanYalta, TulinSivri, NasirYetkin, Ertan2024-06-122024-06-1220130167-52731874-1754https://doi.org/10.1016/j.ijcard.2012.12.039https://hdl.handle.net/20.500.14551/20085Neurohormones (NHs) in the cascade of the arginine vasopressin (AVP) system have drawn particular attention in the recent years. Copeptin, the C-terminal portion of provasopressin, is a novel NH of the AVP system, and is known to be co-released with AVP from hypothalamus (neurohypophysis). As a surrogate marker of the AVP system, copeptin has gradually replaced AVP in several clinical studies largely due to its structural and methodological advantages. Copeptin has been regarded as a marker of non-specific stress response, and has also been suggested to have clinical implications in a variety of non-cardiovascular (pneumonia, sepsis, etc.) and cardiovascular conditions (heart failure and acute coronary syndromes (ACSs, etc.)). However, current data on relation of copeptin with other cardiovascular conditions (arrhythmias, etc.) are still insufficient. The present review primarily focuses on general features of copeptin, its general clinical implications, and specifically aims to cover its potential clinical value in a variety of cardiovascular conditions. (C) 2012 Elsevier Ireland Ltd. All rights reserved.en10.1016/j.ijcard.2012.12.039info:eu-repo/semantics/closedAccessCopeptinArginine VasopressinCardiovascular DiseaseClinical ImplicationTerminal Provasopressin CopeptinAcute Myocardial-InfarctionChronic Heart-FailureArginine-Vasopressin IncreasesGerman Competence NetworkHigh-Sensitivity TroponinC-Reactive ProteinNatriuretic PeptideRisk StratificationPrognostic MarkerReview Article167517501759Q1WOS:0003235696000282-s2.0-8488330378023298558Q1